BiotechTube
Soley Therapeutics

Soley Therapeutics

Cambridge, United States· Est.
soleytherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

Soley Therapeutics, founded in 2016 and based in Cambridge, USA, is a private biotech pioneering a novel drug discovery paradigm. The company's core platform uses living cells under stress as information-rich sensors, applying proprietary imaging and AI to map cellular responses and uncover new therapeutic mechanisms, particularly for hard-to-drug targets like protein-protein interactions. This biology-first approach aims to generate a pipeline of first-in-class small molecule drugs with improved selectivity and safety profiles for complex diseases in oncology and inflammation. Soley is currently in the pre-clinical stage, advancing its platform and initial programs.

OncologyInflammatory Diseases

Technology Platform

Proprietary 'biology-first' platform using living human cells as sensors under stress. Integrates high-content imaging, automation, and AI/ML to map whole-cell behavioral responses and deconvolve novel therapeutic mechanisms, with a focus on protein-protein interactions.

Funding History

1
Total raised:$200M
PIPE$200M

Opportunities

The platform targets the high-value, underserved niche of drugging protein-protein interactions, a key driver in oncology and inflammation.
Success could enable a prolific pipeline of first-in-class medicines with better early insights into safety and efficacy.
The integrated AI/biology approach also presents opportunities for strategic partnerships with larger pharma companies seeking to augment their discovery capabilities.

Risk Factors

High technical risk that the complex phenotypic data cannot be reliably translated into successful clinical drugs.
Significant competition in the AI-driven drug discovery space from other well-funded startups and pharma initiatives.
As a pre-revenue private company, it faces funding and execution risks dependent on capital markets and the ability to attract specialized talent.

Competitive Landscape

Soley operates in the competitive AI/ML drug discovery sector, competing with companies like Recursion, Exscientia, Insitro, and Relay Therapeutics. Its differentiation is its specific 'biology-first' emphasis on whole-cell phenotypic sensing and mapping, rather than a purely computational or target-centric approach. It must prove its platform yields better-quality chemical starting points or novel mechanisms than competitors.

More companies in AI / Machine Learning →More companies in United States →